Skip to content
Hair Pipeline
← Back to the pipeline

VDPHL-01 (oral minoxidil)

Low-dose oral minoxidil, formally trialled for the first time.

Phase 3OralPotassium channel opener
Developed by
Veradermics
Current phase
Phase 3

Large confirmatory trials. The last step before filing.

Indications
Androgenetic alopecia
Also known as
VDPHL01
Last public activity
August 2026
Record confidence
Medium

Why it matters

Dermatologists already prescribe low-dose oral minoxidil off-label at scale. What has never existed is a proper Phase 3 dataset and an approved label. That would change prescribing confidence far more than a new molecule would.

Development history

  1. Phase 2/3Phase 3

    First Phase 3 trial on record: NCT06972264 — Safety and Efficacy of VDPHL01 in Males With AGA

    ClinicalTrials.gov ↗
  2. Phase 2Phase 2/3

    First Phase 2/3 trial on record: NCT06724614 — Efficacy and Safety of VDPHL01 in Males With AGA

    ClinicalTrials.gov ↗
  3. Phase 2

    First Phase 2 trial on record: NCT06527365 — Safety and Efficacy of VDPHL01 in Males and Females With AGA

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT07146022Phase 3ACTIVE NOT RECRUITING

    Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

    Veradermics, Inc. · n=552 · July 2025

  • NCT06972264Phase 3ACTIVE NOT RECRUITING

    Safety and Efficacy of VDPHL01 in Males With AGA

    Veradermics, Inc. · n=480 · March 2025

  • NCT06724614Phase 2/3ACTIVE NOT RECRUITING

    Efficacy and Safety of VDPHL01 in Males With AGA

    Veradermics, Inc. · n=480 · November 2024

  • NCT06527365Phase 2ACTIVE NOT RECRUITING

    Safety and Efficacy of VDPHL01 in Males and Females With AGA

    Veradermics, Inc. · n=70 · July 2024

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources